About me

Graduated in Medicine at University of Barcelona (UB) in 2003. In 2008 he obtained a specialty in Medical Oncology, in 2013 he obtained the Extraordinary Doctorate Award from the Autonomous University of Barcelona. Currently the Director Institut of Oncology at Hospital Clínic Barcelona, Professor of Medicine (Medical Oncology) at the UB and Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Lab at IDIBAPS. Furthermore, he is the Head of the Breast Cancer programme at IOB- Quiron salud as well as CEO and co-founder of the spin-off called Reveal Genomics, where has been developed the HER2DX® diagnostic test just recognized by TIME as one of the best inventions of 2022.

Featured publications

Featured Projects

  • Identification of mechanisms of response to CDK4/6 inhibition in hormone receptor-positive breast cancer

    Principal investigator: Aleix Prat Aparicio
    Funder: IRB (Participante); Fundació La Marató de TV3 ; IDIBELL (Participante); IDIBAPS (Sede o evento)
    Code: 201935-30-31-32
    Duration: 30/07/2020 - 29/07/2023
  • Adoptive cell therapy using CD3+/PD1+ tumor infiltrating lymphocytes in patients with advanced breast cancer

    Principal investigator: Aleix Prat Aparicio
    Funder: AECC, Fundación Científica Asociación Española Contra el Cáncer ; Hospital Clinic de Baarcelona (Participante); Clínica Universidad de Navarra (Participante); Vall d'Hebron Institut d'Oncologia (Participante); HOSPITAL UNIVERSITARIO 12 DE OCTUBRE (Partic
    Code: GCAEC19010PRAT
    Duration: 01/12/2019 - 30/11/2024
  • AACR 2019 - Tailoring systemic treatment of Luminal B breast cancer

    Principal investigator: Patricia Galvan, Aleix Prat Aparicio
    Funder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer Research
    Code: BCRF_AACR_18_001
    Duration: 01/07/2019 - 30/06/2021
  • Caracterización de los linfocitos T CD8+/PD1+ en cáncer de mama avanzado receptor hormonal-positivo con un fenotipo agresivo HER2-enriched.

    Principal investigator: Aleix Prat Aparicio
    Code: 19-IO-011
    Duration: 01/07/2019 - 30/06/2021
  • Prospective exploratory study for determination of circulating tumor DNA (ctDNA) in blood samples from patients treated for breast cancer in follow-up and without evidence of relapse (B-CRONOS) KEYWORDS : Breast cancer, ctDNA, luminal, high risk

    Principal investigator: Aleix Prat Aparicio
    Funder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Fundación Quiron Salaud ; Fundación Quirón Salud
    Code: TERAPIA_AMIGOS_18_01
    Duration: 11/02/2019 - 10/02/2022